Physician profile
Javed Iqbal
NPI 1023060811
$4,319.01
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,076 · 2020: $1,739 · 2021: $270 · 2022: $85.86 · 2023: $148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $148.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $147.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $1,550.18 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $736.76 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $495.48 | 2019-2023 | Spravato |
| Neurocrine Biosciences, INC. | $290.66 | 2019-2020 | |
| Indivior INC. | $215.87 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $188.02 | 2019 | |
| Allergan, INC. | $174.15 | 2019 | |
| Alkermes, INC. | $143.03 | 2019-2023 | Aristada, Aristada Initio |
| Acadia Pharmaceuticals INC | $119.19 | 2019 | |
| Sunovion Pharmaceuticals INC. | $111.05 | 2019 | |
| Gilead Sciences, INC. | $61.38 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $55.34 | 2021 | |
| Lundbeck LLC | $52.89 | 2019 | |
| Janssen Scientific Affairs, LLC | $42.11 | 2019 | |
| Sk Life Science, INC. | $41.69 | 2020-2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.48 | 2022 | |
| Vanda Pharmaceuticals INC. | $16.73 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Javed Iqbal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.